drugset

Drugs / Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine

Follow last change Nov 2024 re-read 3 minutes ago

Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine

Developed for: COVID-19
Investigated by: Johns Hopkins University · National Institute of Allergy and Infectious Diseases (NIAID) · PPD Development, LP · Sanofi Pasteur, a Sanofi Company

Trials 1

today NCT05518487 · Ph 2

202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT05518487	Feb 2023 → Feb 2024	COVID-19	National Institute of Allergy and Infectious Diseases (NIAID)	Completed	No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	Sanofi-GSK monovalent (B.1.351) CoV2 preS dTM-AS03 COVID-19 vaccine	ClinicalTrials.gov intervention name — accepted as the source's own label NCT05518487 ↗
Modality	Vaccine	“COVID-19 vaccine candidate” NCT05518487 ↗
Route	Intramuscular	“will be administered intramuscularly” NCT05518487 ↗